<DOC>
	<DOCNO>NCT01829490</DOCNO>
	<brief_summary>This Phase I trial evaluate safety immunogenicity ChAdOx1 85A vaccination without MVA85A boost healthy BCG vaccinate adult .</brief_summary>
	<brief_title>Safety Study ChAdOx1 85A Vaccination With Without MVA85A Boost Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subjects must meet follow criterion enter trial : Healthy adult age 1855 year Resident near Oxford ( CCVTM ) Birmingham ( WTCRF ) able travel Oxford vaccination duration trial period No relevant finding medical history physical examination Confirmation prior vaccination BCG le 6 month prior project trial vaccination date ( visible BCG scar examination write documentation ) Allow Investigators discuss individual 's medical history GP Use effective contraception duration trial period ( female ) Refrain blood donation trial Give write informed consent Allow Investigator register subject detail confidential database prevent concurrent entry clinical trial Able willing ( Investigator 's opinion ) comply trial requirement Subjects must meet none follow criterion enter trial : Laboratory evidence screen latent M. tb infection indicate positive ELISpot response ESAT6 CFP10 antigens Clinical , radiological , laboratory evidence current active TB disease Shared residence within one year prior day 0 individual antituberculosis treatment culture smearpositive pulmonary tuberculosis Previous vaccination recombinant MVA , FP adenoviral vector Clinically significant history skin disorder , allergy , immunodeficiency ( include HIV ) , cancer ( except BCC CIS ) , cardiovascular disease , gastrointestinal disease , liver disease , renal disease , endocrine disorder , neurological illness , psychiatric disorder , drug alcohol abuse History serious psychiatric condition Concurrent oral systemic steroid medication concurrent use immunosuppressive agent History anaphylaxis vaccination allergy likely exacerbate component trial vaccine include egg Any abnormality screen blood urine test deem clinically significant may compromise safety subject trial Positive HBsAg , HCV HIV antibody Female currently lactate , confirmed pregnancy intention become pregnant trial period Use investigational medicinal product nonregistered drug , live vaccine , medical device 30 day prior dose trial vaccine , plan use trial period Administration immunoglobulins and/or blood product within three month precede plan trial vaccination date Any significant disease , disorder , finding , , opinion Investigator , may either put subject risk may influence result trial may affect subject 's ability participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>